Reuters reported at 7:39 AM ET on Friday, November 20, 2026, that a Merck drug lengthened survival for patients with advanced stomach and esophageal cancers in a clinical trial.
What happened
Reuters reported at 7:39 AM ET on Friday, November 20, 2026, that a Merck medicine extended how long patients lived in a trial of advanced cancers of the stomach and the esophagus (the food pipe). The Reuters item as available to us carries only its headline, so we have no further detail on the drug, the size of the benefit or the trial design. Merck's own statement on the result is not among the reports we have.
How the stock has moved
Merck (MRK) traded at $133.40 in pre-market trading, before the regular session opens, up 0.50% from Thursday's close of $132.74. That is the move since the Reuters report appeared and from the prior close.
| Measure | Value |
|---|---|
| Price, pre-market trading | $133.40 |
| Since the close before the first report (Thursday, November 19, 2026) | +0.50% |
| Change from the close on Thursday, November 19, 2026 | +0.50% |
| Market value at the close on Thursday, November 19, 2026 | $327.24 billion |
Source: Stock quote; the close before the first report from our saved closes · as of November 20, 2026 at 7:54 AM ET · Shows what the stock did after the news was first reported, not why.
Its suppliers and customers
Company filings name three suppliers of Merck: Verona Pharma, Sidera Therapeutics and Doctor Fultz Pharma. None is listed on an exchange, so none has a share price, and none has traded since its last close. No customers are on file.
| Company | Role | Stock | Since last close |
|---|---|---|---|
| Verona Pharma | Supplier | Not listed | — |
| Sidera Therapeutics | Supplier | Not listed | — |
| Doctor Fultz Pharma | Supplier | Not listed | — |
Source: Relationships named in company filings (Earnings call transcript); stock quotes · as of November 20, 2026 at 7:54 AM ET · A supplier or customer moving the same day is not evidence that one move caused the other.